14,302 Shares in DaVita Inc. (NYSE:DVA) Purchased by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. purchased a new position in shares of DaVita Inc. (NYSE:DVA) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 14,302 shares of the company’s stock, valued at approximately $2,149,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. MML Investors Services LLC grew its holdings in DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock worth $869,000 after purchasing an additional 68 shares during the period. Exchange Traded Concepts LLC boosted its holdings in shares of DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock worth $133,000 after acquiring an additional 68 shares during the period. Impact Partnership Wealth LLC boosted its holdings in shares of DaVita by 3.7% during the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock worth $290,000 after acquiring an additional 70 shares during the period. Contravisory Investment Management Inc. boosted its holdings in shares of DaVita by 1.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock worth $910,000 after acquiring an additional 73 shares during the period. Finally, Nilsine Partners LLC raised its position in shares of DaVita by 0.8% in the fourth quarter. Nilsine Partners LLC now owns 11,160 shares of the company’s stock valued at $1,669,000 after buying an additional 92 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. StockNews.com upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Thursday. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. Finally, Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $166.33.

DaVita Stock Up 6.4 %

Shares of DVA opened at $153.15 on Thursday. DaVita Inc. has a one year low of $125.64 and a one year high of $179.60. The company has a market cap of $12.25 billion, a P/E ratio of 14.26, a P/E/G ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The firm has a 50 day simple moving average of $153.05 and a two-hundred day simple moving average of $156.75.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.